Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit
03 avr. 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting
02 avr. 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates
28 mars 2019 08h00 HE
|
Rubius Therapeutics
Investigational New Drug Application Cleared for First-Ever Red Cell Therapeutic™, RTX-134, for Treatment of Phenylketonuria Data from Company’s Oncology Pipeline to be Presented at AACR 2019 Annual...
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
25 mars 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
19 mars 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
11 mars 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely...
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
27 févr. 2019 16h35 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely...
Rubius Therapeutics to Participate at Upcoming Investor Conferences
19 févr. 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely...
Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference
07 janv. 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company that is generating red blood cells and bioengineering them into an entirely new...
Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
27 déc. 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced...